NEWS & EVENTS

Catalent today welcomed the news that DiaMedica Therapeutics has received U.S. FDA approval to commence Phase 2 clinical trials of its lead candidate, DM199, for chronic kidney disease.

Catalent today announced that Christopher Hepler, Manager, Catalent Biologics Analytical Development, has been invited to speak on ways to improve assay development at the upcoming CASSS WCBP symposium, which will be held on Jan 28 – 30, 2020.

Catalent today announced the appointment of Karen Flynn as President of Biologics and Chief Commercial Officer. Ms. Flynn has also joined the company’s Executive Leadership Team and will report to Alessandro Maselli, Catalent’s President and Chief Operating Officer.

Catalent today announced the completion of the purchase of Bristol-Myers Squibb’s biologics, sterile, and oral solid dose product manufacturing and packaging facility in Anagni, Italy.

Catalent today announced that Greg Bleck, Ph.D., Global Head of R&D, Catalent Biologics will present at the upcoming annual PEGS Europe conference, which will be held at the Lisboa Congress Center, Lisbon, Portugal, on Nov. 18 – 22, 2019.

Catalent today announced it will present at the upcoming World Orphan Drug Congress Europe, being held at Hotel Sofia, Barcelona, Spain on Nov. 12 – 14, 2019.

Catalent, today announced the launch of its next-generation cell line development technology, GPEx® Boost.

Catalent, today announced that professor David Schaffer has been appointed to the advisory board of the company’s biologics business.

Catalent today announced that Alex Haig, Senior Director, Engineering will present at the Pharma Forum, to be held at the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. 18 – 19, 2019.